Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis' AveXis buys AstraZeneca site in Colorado as it anticipates gene therapy launch
Fierce Pharma
Tue, 04/2/19 - 11:54 am
Tags:
Novartis, biotech, AveXix, Colorado, gene therapies, drug manufacturing
Did Novartis hand out kickbacks or host educational dinners? A jury may decide
Fierce Pharma
Mon, 04/1/19 - 10:58 pm
Tags:
Novartis, kickbacks, physicians, physician payments
Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre
Xconomy
Mon, 04/1/19 - 10:31 am
Tags:
Novartis, IFM Tre, M&A, anti-inflammatory, inflammation
2 Blockbuster Gene Therapy Programs to Watch in 2019
Motley Fool
Sun, 03/31/19 - 03:42 pm
Tags:
gene therapy, Zolgensma, Novartis, Bluebird Bio, LentiGlobin
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Motley Fool
Sat, 03/30/19 - 12:44 pm
Tags:
Alzheimer's disease, Biogen, aducanumab, Otsuka, Axsome Therapeutics, Amgen, Novartis, Avanir, AVP-786, AXS-05, AMG520
FDA approves Novartis' Mayzent for MS
BioCentury
Tue, 03/26/19 - 11:02 pm
Tags:
FDA, Novartis, Mayzent, siponimod, relapsing multiple sclerosis
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
Sun, 03/24/19 - 12:02 pm
Tags:
FDA, Novartis, Ascendis, Eiger BioPharmaceuticals, Proteostasis Therapeutics, Fibrocell Science, Supernus Pharmaceuticals, FibroGen, INSYS Therapeutics
Novartis launches COPD inhalers in China
Drug Delivery Business News
Fri, 03/22/19 - 11:54 am
Tags:
Novartis, COPD, China, Ultibro Breezhaler, Seebri Breezhaler, devices
Conatus and Novartis suffer another midphase NASH flop
Fierce Biotech
Fri, 03/22/19 - 11:51 am
Tags:
Conatus, Novartis, NASH, emricasan, clinical trials
Novartis says listing of Alcon eye care business expected on April 9
Yahoo/Reuters
Fri, 03/22/19 - 10:04 am
Tags:
Alcon, Novartis, spinoffs, eye health
Novartis’ Alcon picks up PowerVision for $285m
Mass Device
Mon, 03/18/19 - 05:09 pm
Tags:
Novartis, Alcon, PowerVision, M&A, interocular lens, devices
American College of Cardiology Conference Roundup - day 1
CP Wire
Sun, 03/17/19 - 01:25 pm
Tags:
American College of Cardiology, Novartis, Entresto, heart failure, Edwards Lifesciences, Apple, TAVR, wearables, clinical trials, Apple Watch, atrial fibrillation
Sun, 03/17/19 - 01:21 pm
Tags:
American College of Cardiology, Novartis, Entresto, heart failure, Edwards Lifesciences, Apple, TAVR, wearables, clinical trials, Apple Watch, atrial fibrillation
CEO of Novartis’ generics unit quits, sparking sale speculation
Pharmaforum
Thu, 03/14/19 - 10:06 am
Tags:
Novartis, Sandoz, generics, M&A, Richard Francis, biosimilars
New insights emerge in an effort to repurpose Novartis’ cancer drug Tasigna in Parkinson’s disease
Fierce Biotech
Wed, 03/13/19 - 04:36 pm
Tags:
Novartis, Tasigna, Parkinson's Disease
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Wed, 03/13/19 - 10:13 am
Tags:
Celgene, Novartis, ozanimod, MS, multiple sclerosis, patents, Bristol-Myers Squibb, M&A
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Pharmaceutical Business Review
Tue, 03/5/19 - 10:00 am
Tags:
Novartis, Cosentyx, China, psoriasis
Seventure holds first close of €200M microbiome fund
Fierce Biotech
Tue, 03/5/19 - 09:59 am
Tags:
Seventure Partners, microbiome, Novartis, startups
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
RAPS.org
Mon, 03/4/19 - 12:08 pm
Tags:
Novartis, Janssen, JNJ, psoriasis, false advertising, Tremfya
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Fierce Pharma
Fri, 03/1/19 - 11:56 am
Tags:
JNJ, Janssen, Tremfya, psoriasis, Novartis, Cosentyx, Eli Lilly, Taltz

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.